Lv3
210 积分 2022-08-09 加入
Analysis of China-to-West pharmaceutical licensing deals in 2024
12小时前
求助中
DDR1-targeted therapies: current limitations and future potential
25天前
已完结
Research progress of DDR1 inhibitors in the treatment of multiple human diseases
25天前
已完结
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
1个月前
已完结
Obstacles and opportunities in studying melanoma in Latin America
2个月前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
4个月前
已完结
Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer
4个月前
已完结
Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors
4个月前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
4个月前
已完结
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics
5个月前
已完结
皖公网安备34019202002308
